AVITA Medical names David O'Toole CFO; $450K salary, 150K options

AVITA Medical, Inc.

David O'Toole appointed CFO effective June 15, 2023; brings 30+ years biotech/life sciences finance experience.
Annual base salary of $450,000; eligible for performance bonus up to 40% of base (max 90% combined).
Granted 150,000 stock options under 2020 Omnibus Plan vesting in 3 equal annual installments.
On termination without cause: 12 months base salary plus health benefits, unvested options accelerated for 3 months.
Most recently CFO of Opiant Pharmaceuticals (acquired by Indivior); previously CFO of Soleno Therapeutics.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David O'Toole

Chief Financial Officer

RCEL · AVITA Medical, Inc.

Effective: 2023-06-15
Filed: June 16, 2023, 7:59 PM ET

AVITA Medical, Inc. (the “Company”) entered into an Executive Employment Agreement (the “Agreement”) with David O’Toole with an effective date of June 15, 2023 (the “Effective Date”), pursuant to which Mr. O’Toole will serve as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

David O'Toole was appointed as Chief Financial Officer at AVITA Medical, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

AVITA Medical, Inc. (the “Company”) entered into an Executive Employment Agreement (the “Agreement”) with David O’Toole with an effective date of June 15, 2023 (the “Effective Date”), pursuant to which Mr. O’Toole will serve as the Company’s Chief Financial Officer.

View on SEC.gov

AVITA Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-168182

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.